Search research articles
Contact Us
Filters
Showing results (231-240 of 242) with videos related to
Page
of 25
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 13, 2015
Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients
M Hecht, L Zimmer, C Loquai, et al.
The British Journal of Dermatology
|
February 18, 2020
GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma
E Livingstone, A Zaremba, S Horn, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 23, 2023
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial
E Livingstone, H Gogas, L Kandolf-Sekulovic, et al.
ESMO Open
|
May 9, 2025
Early switch from run-in with targeted to immunotherapy in advanced BRAF<sup>V600</sup>-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial
E Livingstone, H J Gogas, L Kandolf, et al.
The Journal of Investigative Dermatology
|
September 17, 2023
Type 2 T-Cell Responses against Distinct Epitopes of the Desmoglein 3 Ectodomain in Pemphigus Vulgaris
Dario Didona, Luca Scarsella, Christoph Hudemann, et al.
Science Translational Medicine
|
June 24, 2021
A biliary immune landscape map of primary sclerosing cholangitis reveals a dominant network of neutrophils and tissue-resident T cells
Christine L Zimmer, Erik von Seth, Marcus Buggert, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 6, 2019
Sequence-dependent cross-resistance of combined radiotherapy plus BRAF<sup>V600E</sup> inhibition in melanoma
B Shannan, J Matschke, H Chauvistré, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 1, 2019
Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study
L Khoja, E G Atenafu, S Suciu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 9, 2025
Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma
K C Kähler, J C Hassel, M Ziemer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 2, 2021
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma
C N Owen, X Bai, T Quah, et al.
Page
of 25
Search research articles
Search
Showing results (231-240 of 242) with videos related to
Sort By:
Page
of 25
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 13, 2015
Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients
M Hecht, L Zimmer, C Loquai, et al.
The British Journal of Dermatology
|
February 18, 2020
GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma
E Livingstone, A Zaremba, S Horn, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 23, 2023
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial
E Livingstone, H Gogas, L Kandolf-Sekulovic, et al.
ESMO Open
|
May 9, 2025
Early switch from run-in with targeted to immunotherapy in advanced BRAF<sup>V600</sup>-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial
E Livingstone, H J Gogas, L Kandolf, et al.
The Journal of Investigative Dermatology
|
September 17, 2023
Type 2 T-Cell Responses against Distinct Epitopes of the Desmoglein 3 Ectodomain in Pemphigus Vulgaris
Dario Didona, Luca Scarsella, Christoph Hudemann, et al.
Science Translational Medicine
|
June 24, 2021
A biliary immune landscape map of primary sclerosing cholangitis reveals a dominant network of neutrophils and tissue-resident T cells
Christine L Zimmer, Erik von Seth, Marcus Buggert, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 6, 2019
Sequence-dependent cross-resistance of combined radiotherapy plus BRAF<sup>V600E</sup> inhibition in melanoma
B Shannan, J Matschke, H Chauvistré, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 1, 2019
Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study
L Khoja, E G Atenafu, S Suciu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 9, 2025
Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma
K C Kähler, J C Hassel, M Ziemer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 2, 2021
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma
C N Owen, X Bai, T Quah, et al.
Page
of 25